Clinical Trials CFZ533

INNODIA is now collaborating with Novartis Pharmaceuticals on a study to evaluate the safety of the investigational drug CFZ533 (Iscalimab) in young adult and pediatric patients with recent onset type 1 diabetes. The study will evaluate whether CFZ533 can protect the remaining pancreatic beta cells. The study is now closed to new enrollment.